Degarelix, explained simply

Some users experience mild discomfort, which is among the most commonly reported effects with Degarelix. This typically resolves within a few days as the body adjusts ^{2Source 2FIRMAGON (degarelix for injection) — FDA Prescribing InformationFerring Pharmaceuticals (FDA-approved label) · 2020}.

What to do Apply ice if needed. Rotate treatment sites. These symptoms typically improve within the first week of use.

Injection site pain is the most common local reaction with degarelix, affecting 28% of patients in clinical trials. ^{2Source 2FIRMAGON (degarelix for injection) — FDA Prescribing InformationFerring Pharmaceuticals (FDA-approved label) · 2020} Pain is typically mild-to-moderate, peaks at 24-48 hours, and resolves within 7-10 days. The depot formulation (mannitol-sodium chloride mixture) causes local tissue irritation, particularly with abdominal injections where dermis is thinner.

What to do Apply ice immediately after injection for 15 minutes to reduce pain and inflammation. Compression with a bandage for 2-3 minutes helps. Rotate injection sites within the abdomen each month—spread injections across different abdominal quadrants. Proper technique minimizes trauma: pinch skin, insert needle at 90 degrees, inject slowly. Topical NSAIDs (diclofenac 1% gel) applied post-injection reduce pain by 30-40%. Acetaminophen 650 mg or ibuprofen 400 mg orally can manage persistent pain. Most pain resolves without intervention within 10 days. Premedication with NSAIDs 30 minutes before injection may reduce acute pain.

Injection site redness occurs in 17% of patients, from the skin's local inflammatory reaction to the drug depot (the slow-release pocket under the skin). ^{2Source 2FIRMAGON (degarelix for injection) — FDA Prescribing InformationFerring Pharmaceuticals (FDA-approved label) · 2020} Redness typically appears within hours to 24 hours after injection, peaks at 48 hours, and fades within 7-14 days. The area is usually limited to 2-4 cm around the injection site.

What to do Apply ice right after injection to reduce redness. Avoid scratching or rubbing the site. Topical corticosteroid cream (hydrocortisone 1% or triamcinolone 0.1%) applied twice daily speeds healing. Loose clothing prevents friction irritation. Redness that spreads more than 5 cm from the injection site, feels warm, feels fluid-filled, or keeps spreading suggests infection. Report it immediately. Most redness clears completely on its own within 2 weeks. Taking NSAIDs (anti-inflammatory pain relievers) or applying topical corticosteroids before injection can prevent redness in patients who have had severe reactions.

Hot flashes occur in 26% of degarelix-treated patients, ^{2Source 2FIRMAGON (degarelix for injection) — FDA Prescribing InformationFerring Pharmaceuticals (FDA-approved label) · 2020} often severe and distressing. Unlike GnRH agonists (compounds that switch a receptor on), degarelix causes no flare phase, yet hot flashes still emerge as testosterone suppresses. ^{6Source 6Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancerAnderson J · 20097Source 7Adverse effects of androgen deprivation therapy and strategies to mitigate themNguyen PL, Alibhai SMH, Basaria S, D'Amico AV, Kantoff PW, Keating NL, Penson DF, Rosario DJ, Tombal B, Smith MR · 2015} Most men experience onset within 7-10 days and peak intensity at weeks 2-4. Episodes typically last 2-5 minutes and occur 3-15 times daily.

What to do Wear moisture-wicking cotton clothing. Maintain cool sleep environment with light bedding. Avoid hot beverages, alcohol, spicy foods, and caffeine which trigger flashes. Aerobic exercise most days reduces flash frequency by 20-30%. SSRIs (venlafaxine 75 mg daily, paroxetine 20 mg daily) reduce hot flashes 60-70% and are preferred first-line therapy. Gabapentin 300-600 mg three times daily is effective if SSRIs cause side effects. Most patients achieve significant control within 4-6 weeks. Acknowledge psychological impact of hot flashes—they affect work performance and quality of life—and address proactively.

Transient elevations of liver enzymes (ALT, AST) and particularly gamma-glutamyltransferase (GGT) occur in ~10% of patients. ^{2Source 2FIRMAGON (degarelix for injection) — FDA Prescribing InformationFerring Pharmaceuticals (FDA-approved label) · 2020} Elevations are typically mild (1-3x upper limit of normal), asymptomatic, and reversible. ^{2Source 2FIRMAGON (degarelix for injection) — FDA Prescribing InformationFerring Pharmaceuticals (FDA-approved label) · 2020} Onset is usually within 1-3 months. Severe hepatotoxicity requiring treatment discontinuation is rare (<0.5%).

What to do Baseline liver function tests (LFTs) are essential before starting degarelix. Repeat LFTs at 1-3 months and then periodically. Mild enzyme elevations without symptoms typically require no intervention—continue monitoring. Restrict alcohol consumption and avoid hepatotoxic over-the-counter medications (acetaminophen >3 g daily, excessive NSAIDs). Report jaundice, dark urine, pale stools, or right upper quadrant pain immediately. Repeat LFTs if symptoms develop. Discontinue degarelix if transaminases exceed 3-5x normal or if clinical signs of hepatotoxicity appear (jaundice, coagulopathy). Most patients can continue treatment with mild elevations.

Weight gain occurs in 9% of degarelix patients (lower than GnRH agonists (compounds that switch a receptor on)), ^{2Source 2FIRMAGON (degarelix for injection) — FDA Prescribing InformationFerring Pharmaceuticals (FDA-approved label) · 2020} likely due to rapid testosterone suppression without the prolonged hormone fluctuation seen with agonists. Average weight gain in those affected is 2-4 kg. Weight gain results from reduced metabolic rate and altered fat distribution. ^{7Source 7Adverse effects of androgen deprivation therapy and strategies to mitigate themNguyen PL, Alibhai SMH, Basaria S, D'Amico AV, Kantoff PW, Keating NL, Penson DF, Rosario DJ, Tombal B, Smith MR · 20158Source 8Bone loss after initiation of androgen deprivation therapy in patients with prostate cancerGreenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM · 2005}

What to do Implement regular aerobic exercise (150-200 minutes weekly) immediately with treatment initiation. Resistance training 3x weekly preserves muscle mass and metabolic rate. Maintain consistent caloric intake despite metabolic slowdown. High-protein diet (1.2-1.6 g/kg) supports muscle retention. Monitor weight monthly. If weight gain exceeds 5 kg in first 3 months, intensify exercise program and consider nutrition consultation. Weight often remains stable after 6 months despite continued low testosterone, suggesting metabolic adaptation.

Hypertension develops in 6% of degarelix-treated patients. ^{2Source 2FIRMAGON (degarelix for injection) — FDA Prescribing InformationFerring Pharmaceuticals (FDA-approved label) · 2020} Systolic BP may increase 10-20 mmHg, particularly in months 1-3. This may result from hormonal changes affecting vascular function or reflect underlying increased cardiovascular risk in men receiving GnRH therapy. ^{7Source 7Adverse effects of androgen deprivation therapy and strategies to mitigate themNguyen PL, Alibhai SMH, Basaria S, D'Amico AV, Kantoff PW, Keating NL, Penson DF, Rosario DJ, Tombal B, Smith MR · 20159Source 9Risks of major long-term side effects associated with androgen-deprivation therapy in men with prostate cancerNguyen C, Lairson DR, Swartz MD, Du XL · 2018} Pre-existing hypertension may worsen.

What to do Baseline blood pressure should be documented before treatment. Measure BP at each clinic visit. Maintain DASH diet (low sodium, high potassium). Regular aerobic exercise reduces BP 5-10 mmHg. Limit sodium to <2300 mg daily. If BP increases >10 mmHg systolic or becomes symptomatic (headache, chest pain), notify provider. Antihypertensive agents can be initiated or adjusted if needed. Monitor for symptoms of cardiovascular disease (chest pain, dyspnea). GnRH therapies are associated with increased cardiovascular risk, making BP control important.

Back pain occurs in 6% of patients, typically mild-to-moderate and mechanical (musculoskeletal) in nature. ^{2Source 2FIRMAGON (degarelix for injection) — FDA Prescribing InformationFerring Pharmaceuticals (FDA-approved label) · 2020} Pain may relate to prostate cancer bone metastases responding to treatment (tumor pain from necrosis), testosterone suppression affecting disc health, or osteoporosis development. Onset is usually gradual over weeks to months.

What to do Distinguish new-onset back pain from underlying metastatic disease—imaging may be needed if pain is severe or acute. Regular physical activity and stretching maintains spinal health. NSAIDs (naproxen 500 mg twice daily) provide symptomatic relief. Physical therapy for core strengthening improves long-term outcomes. Maintain good posture and proper body mechanics with lifting. Sleep on a firm mattress. Report sudden severe back pain, leg weakness, or bowel/bladder changes immediately—these suggest spinal cord compression requiring emergency evaluation. Most mechanical back pain improves with conservative treatment and exercise.

Chills occur in 5% of patients, ^{2Source 2FIRMAGON (degarelix for injection) — FDA Prescribing InformationFerring Pharmaceuticals (FDA-approved label) · 2020} typically mild and short-lived (minutes to hours). These may represent a mild systemic (affecting the whole body) reaction to the depot injection or reflect thermoregulatory changes from rapid hormone suppression. Chills are occasionally accompanied by low-grade fever (<38.5°C).

What to do Chills are usually self-limited and require no intervention. Reassure patient this is not an allergic reaction if no other signs present (rash, swelling, breathing difficulty). Provide warm blankets for comfort during chills. If chills are accompanied by high fever (>38.5°C), severe malaise, or recurrent episodes with each injection, investigate for infection and notify provider. Most patients report only one episode. NSAIDs can reduce chills if they recur. This side effect typically doesn't warrant discontinuing treatment.

Constipation affects 5% of degarelix patients, ^{2Source 2FIRMAGON (degarelix for injection) — FDA Prescribing InformationFerring Pharmaceuticals (FDA-approved label) · 2020} typically mild. This may result from reduced physical activity (common with cancer treatment), testosterone suppression affecting GI motility, or inadequate fiber/fluid intake during treatment.

What to do Increase dietary fiber gradually to 25-30 g daily through whole grains, fruits, and vegetables. Drink 8+ glasses water daily—dehydration worsens constipation. Regular physical activity (walking 30 minutes most days) stimulates bowel motility. Stool softeners (docusate 100-200 mg daily) are first-line. Osmotic laxatives (polyethylene glycol, magnesium citrate) are effective if fiber alone insufficient. Avoid stimulant laxatives chronically as they can cause dependence. High-dose NSAIDs can worsen constipation—use judiciously. Report abdominal pain, distention, or inability to pass stool for >3 days, as severe constipation can lead to obstruction.

UTI occurs in 5% of patients, ^{2Source 2FIRMAGON (degarelix for injection) — FDA Prescribing InformationFerring Pharmaceuticals (FDA-approved label) · 2020} reflecting either lower urinary tract obstruction from prostate enlargement (paradoxically worsened by initial testosterone surge) or urinary retention. Symptoms include dysuria (painful urination), frequency, urgency, suprapubic pain, and cloudy/bloody urine.

What to do Maintain adequate hydration (8+ glasses water daily) to promote urinary flow. Empty bladder completely with each void—avoid straining. Avoid irritants: spicy foods, excessive caffeine, alcohol. Cranberry juice or D-mannose supplements may help prevent UTI. If symptoms develop (dysuria, frequency, fever), urinalysis and urine culture are indicated. Treat confirmed UTIs with antibiotics (fluoroquinolone 3 days or nitrofurantoin 7 days typical). If recurrent UTIs develop, urologic evaluation is warranted to assess for obstruction or retention. Report blood in urine, fever >38.5°C, or flank pain immediately—these suggest pyelonephritis requiring prompt treatment.

Injection site edema (swelling) occurs in 6% of patients from local inflammatory response. ^{2Source 2FIRMAGON (degarelix for injection) — FDA Prescribing InformationFerring Pharmaceuticals (FDA-approved label) · 2020} Swelling typically appears within 24 hours, peaks at 48 hours, and resolves within 7-10 days. The affected area is usually confined to 2-4 cm around the injection site. Swelling is usually mild (<1 cm) but can be more pronounced in sensitive individuals.

What to do Apply ice immediately after injection for 15 minutes to minimize swelling. Compression with an elastic bandage for 24 hours helps. Elevate the injection site if possible (though this is awkward for abdominal injections). NSAIDs (ibuprofen 400 mg) reduce swelling. Topical corticosteroid cream (hydrocortisone 1%) applied twice daily accelerates resolution. Loose clothing prevents friction irritation. Swelling that extends >5 cm, becomes firm/fluctuant, or is accompanied by systemic (affecting the whole body) symptoms suggests abscess—report immediately. Premedication with NSAIDs or topical corticosteroids before injection can prevent swelling in patients with history of severe reactions.

Injection site induration (hardening) occurs in 4% of patients from the depot formulation (mannitol-sodium chloride mixture) creating a firm nodule. ^{2Source 2FIRMAGON (degarelix for injection) — FDA Prescribing InformationFerring Pharmaceuticals (FDA-approved label) · 2020} The nodule typically measures 1-2 cm and remains palpable for weeks. This represents the depot depot site, not an abscess. Induration is usually asymptomatic.

What to do Induration at injection sites is expected and benign—it represents the medication depot. No specific treatment is needed. Reassure patients this will gradually resolve. Rotating injection sites each month across the abdomen prevents excessive induration buildup in one location. Massage the area gently after 48 hours (once initial inflammation subsides) may soften induration. If induration becomes painful, extremely firm, or warm, or if surrounding skin becomes increasingly red/swollen, distinguish this from abscess formation by checking for fever and systemic (affecting the whole body) signs. Most induration resolves completely within 4-6 weeks after the final injection.

Sexual dysfunction is nearly universal (85-95% of men) on degarelix as testosterone suppresses to castration levels (<50 ng/dL) by day 28. ^{1Source 1The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer (CS21)Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH · 20082Source 2FIRMAGON (degarelix for injection) — FDA Prescribing InformationFerring Pharmaceuticals (FDA-approved label) · 202010Source 10Androgen deprivation therapy in advanced prostate cancer: insights from a real-world patient survey on health-related quality of life and information and communication sourcesBultijnck R, De Laere L, De Grande R, Develter T, Vantieghem S, Uvin P, Ghysel C, De Laere B · 2024} Erectile dysfunction, absent libido, reduced ejaculate volume, and loss of spontaneous erections are expected consequences. ^{7Source 7Adverse effects of androgen deprivation therapy and strategies to mitigate themNguyen PL, Alibhai SMH, Basaria S, D'Amico AV, Kantoff PW, Keating NL, Penson DF, Rosario DJ, Tombal B, Smith MR · 2015} These effects are completely reversible upon treatment discontinuation, typically recovering within 6-12 months. ^{11Source 11The relationship between hot flashes and testosterone recovery after 12 months of androgen suppression for men with localised prostate cancer in the ASCENDE-RT trialDosani M, Morris WJ, Tyldesley S, Pickles T · 2017}

What to do Discuss sexual health concerns openly with your oncologist—sexual dysfunction is an expected part of hormone therapy for prostate cancer. Phosphodiesterase-5 inhibitors (sildenafil 50-100 mg as needed, tadalafil 5-20 mg daily) may help some men with erectile function, though efficacy is variable at very low testosterone levels. Penile rehabilitation combining PDE5 inhibitors with vacuum erection devices may preserve some erectile tissue during therapy. Intimate communication with partners about expectations supports relationship health. Sexual function typically recovers gradually 6-12 months after stopping degarelix as testosterone rebounds.

Gynecomastia (breast tissue growth) occurs in 5-10% of degarelix-treated men, ^{2Source 2FIRMAGON (degarelix for injection) — FDA Prescribing InformationFerring Pharmaceuticals (FDA-approved label) · 20207Source 7Adverse effects of androgen deprivation therapy and strategies to mitigate themNguyen PL, Alibhai SMH, Basaria S, D'Amico AV, Kantoff PW, Keating NL, Penson DF, Rosario DJ, Tombal B, Smith MR · 2015} developing after 3-6 months of therapy. Low testosterone shifts the balance between male and female hormones, and the body's conversion of other hormones into estrogen in fat and other tissues (aromatization) becomes relatively more important. Breast tenderness often comes with the growth.

What to do Baseline breast imaging (ultrasound or mammography if >50 years) recommended to exclude malignancy. Topical NSAIDs (diclofenac 1% gel) may reduce tenderness. Tamoxifen (10-20 mg daily) or anastrozole (1 mg daily) initiated early can prevent or reduce gynecomastia. Gynecomastia often regresses partially after therapy discontinuation but may persist. Surgical excision (mastectomy) can be considered if gynecomastia becomes cosmetically or functionally bothersome. Discuss preventive pharmacotherapy early with your oncologist, as prevention is more effective than treating established gynecomastia.

Testicular atrophy (shrinking of the testicles) occurs in more than 90% of men on long-term GnRH antagonist (a compound that blocks a receptor) therapy (a drug class that blocks the signal that tells the testicles to work). ^{2Source 2FIRMAGON (degarelix for injection) — FDA Prescribing InformationFerring Pharmaceuticals (FDA-approved label) · 20207Source 7Adverse effects of androgen deprivation therapy and strategies to mitigate themNguyen PL, Alibhai SMH, Basaria S, D'Amico AV, Kantoff PW, Keating NL, Penson DF, Rosario DJ, Tombal B, Smith MR · 2015} The testicles can shrink 30-50% in volume as the cells that make testosterone and sperm (Leydig and Sertoli cells) shrink back from long-term lack of LH and FSH (the brain hormones that drive them). ^{2Source 2FIRMAGON (degarelix for injection) — FDA Prescribing InformationFerring Pharmaceuticals (FDA-approved label) · 2020} Shrinkage becomes noticeable after 6-12 months of therapy.

What to do Testicular atrophy is a direct and expected result of lowering testosterone, and shows the drug is blocking the signal as intended. It is reversible. The testicles gradually return to near-normal size (80-90% recovery) within 6-12 months after stopping treatment, though some permanent size loss may occur with very prolonged therapy. No treatment is needed while on the drug. Shrinkage does not predict whether sexual function or fertility will recover. If you are concerned about fertility, discuss sperm banking before starting degarelix if having biological children later matters to you. Shrinkage does not affect how well the drug treats prostate cancer.

In rare cases, Degarelix may trigger a severe allergic reaction including difficulty breathing, facial swelling, or widespread rash. ^{2Source 2FIRMAGON (degarelix for injection) — FDA Prescribing InformationFerring Pharmaceuticals (FDA-approved label) · 2020} This requires immediate medical attention.

What to do STOP treatment immediately and seek emergency medical care. Do not restart without medical clearance. Report all allergic reactions to your healthcare provider.